EA039307B1 - Применение фармацевтической композиции, содержащей ингибиторы контрольных точек иммунного ответа, для лечения острого миелоидного лейкоза - Google Patents

Применение фармацевтической композиции, содержащей ингибиторы контрольных точек иммунного ответа, для лечения острого миелоидного лейкоза Download PDF

Info

Publication number
EA039307B1
EA039307B1 EA201890428A EA201890428A EA039307B1 EA 039307 B1 EA039307 B1 EA 039307B1 EA 201890428 A EA201890428 A EA 201890428A EA 201890428 A EA201890428 A EA 201890428A EA 039307 B1 EA039307 B1 EA 039307B1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
tigit
present
antibody
aml
Prior art date
Application number
EA201890428A
Other languages
English (en)
Russian (ru)
Other versions
EA201890428A1 (ru
Inventor
Вальтер Фидлер
Ясмин Веллброк
Хауке Штамм
Феликс Клинглер
Original Assignee
Эмджен Рисерч (Мюник) Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмджен Рисерч (Мюник) Гмбх filed Critical Эмджен Рисерч (Мюник) Гмбх
Publication of EA201890428A1 publication Critical patent/EA201890428A1/ru
Publication of EA039307B1 publication Critical patent/EA039307B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
EA201890428A 2015-08-05 2016-08-05 Применение фармацевтической композиции, содержащей ингибиторы контрольных точек иммунного ответа, для лечения острого миелоидного лейкоза EA039307B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562201461P 2015-08-05 2015-08-05
PCT/EP2016/068726 WO2017021526A1 (en) 2015-08-05 2016-08-05 Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers

Publications (2)

Publication Number Publication Date
EA201890428A1 EA201890428A1 (ru) 2018-07-31
EA039307B1 true EA039307B1 (ru) 2022-01-12

Family

ID=56801503

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890428A EA039307B1 (ru) 2015-08-05 2016-08-05 Применение фармацевтической композиции, содержащей ингибиторы контрольных точек иммунного ответа, для лечения острого миелоидного лейкоза

Country Status (21)

Country Link
US (2) US20170037133A1 (cg-RX-API-DMAC10.html)
EP (1) EP3331915B1 (cg-RX-API-DMAC10.html)
JP (1) JP7170532B2 (cg-RX-API-DMAC10.html)
CN (1) CN108473572B (cg-RX-API-DMAC10.html)
AU (1) AU2016301961B2 (cg-RX-API-DMAC10.html)
DK (1) DK3331915T3 (cg-RX-API-DMAC10.html)
EA (1) EA039307B1 (cg-RX-API-DMAC10.html)
ES (1) ES2861436T3 (cg-RX-API-DMAC10.html)
HU (1) HUE053763T2 (cg-RX-API-DMAC10.html)
IL (1) IL256874B (cg-RX-API-DMAC10.html)
JO (1) JO3620B1 (cg-RX-API-DMAC10.html)
LT (1) LT3331915T (cg-RX-API-DMAC10.html)
MX (1) MX389204B (cg-RX-API-DMAC10.html)
MY (1) MY186582A (cg-RX-API-DMAC10.html)
PH (1) PH12018500120A1 (cg-RX-API-DMAC10.html)
SG (1) SG10202000914VA (cg-RX-API-DMAC10.html)
SI (1) SI3331915T1 (cg-RX-API-DMAC10.html)
TW (1) TWI719041B (cg-RX-API-DMAC10.html)
UA (1) UA125375C2 (cg-RX-API-DMAC10.html)
WO (1) WO2017021526A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201708598B (cg-RX-API-DMAC10.html)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
US10550173B2 (en) 2015-02-19 2020-02-04 Compugen, Ltd. PVRIG polypeptides and methods of treatment
IL254039B2 (en) * 2015-02-19 2023-12-01 Compugen Ltd Anti-pvrig antibodies and methods of use
EP3288570A4 (en) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
JP6786529B2 (ja) * 2015-06-29 2020-11-18 バイオメッド バレー ディスカバリーズ，インコーポレイティド Ｌｐｔ−７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法
US11098130B1 (en) 2015-08-03 2021-08-24 Tasrif Pharmaceutical, LLC Antibodies and antibody fragments against the CD155 receptor and methods of use thereof
RU2756275C2 (ru) 2016-03-01 2021-09-29 Юссум Рисёрч Девелопмент Компани Оф Зэ Хибру Юниверсити Оф Иерусалим Лтд. Антитела, специфические к рецептору полиовируса (pvr) человека
KR102543118B1 (ko) 2016-05-27 2023-06-14 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
KR102585976B1 (ko) 2016-08-17 2023-10-05 컴퓨젠 엘티디. 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
KR102397771B1 (ko) 2016-09-23 2022-05-13 프레드 헛친슨 켄서 리서치 센터 부 조직적합성(h) 항원 ha-1에 대해서 특이적인 tcr 및 이의 용도
MX2019006072A (es) 2016-11-30 2019-08-14 Oncomed Pharm Inc Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
AU2018234830B2 (en) 2017-03-15 2023-03-02 Fred Hutchinson Cancer Center High affinity MAGE-A1-specific TCRs and uses thereof
LT3618863T (lt) 2017-05-01 2023-10-10 Agenus Inc. Anti-tigit antikūnai ir jų panaudojimo būdai
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CA3063563A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Compositions and methods for an improved antitumor immune response
JP7348072B2 (ja) 2017-06-01 2023-09-20 コンピュジェン リミテッド 三重併用抗体療法
WO2018229163A1 (en) * 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
IL272227B2 (en) 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
AU2018314242A1 (en) 2017-08-11 2020-02-13 Fred Hutchinson Cancer Center BRAF-specific TCRs and uses thereof
KR20200041377A (ko) 2017-09-06 2020-04-21 프레드 헛친슨 켄서 리서치 센터 Strep-tag 특이적 결합 단백질 및 그 용도
CN111051349A (zh) 2017-09-06 2020-04-21 弗雷德哈钦森癌症研究中心 Strep-tag特异性嵌合受体及其用途
US12350312B2 (en) 2017-09-06 2025-07-08 Fred Hutchinson Cancer Center Methods for improving adoptive cell therapy
US20210069241A1 (en) 2017-10-20 2021-03-11 Fred Hutchinson Cancer Research Center Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
WO2019102456A1 (en) 2017-11-27 2019-05-31 University Of Rijeka Faculty Of Medicine Immunotoxins for treating cancer
US20220267403A1 (en) 2017-12-01 2022-08-25 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
WO2019140278A1 (en) 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunotherapy targeting core binding factor antigens
MX428543B (es) * 2018-02-28 2025-11-13 Yuhan Corp Anti cuerpos anti tigit y usos de los mismos.
WO2019178356A1 (en) * 2018-03-14 2019-09-19 Dana-Farber Cancer Institute, Inc. Engineered cells, t cell immune modulating antibodies and methods for using the same
SG11202010025YA (en) 2018-05-31 2020-11-27 Glyconex Inc Therapeutic antibodies binding to biantennary lewis b and lewis y antigens
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
US20210340201A1 (en) 2018-08-22 2021-11-04 Fred Hutchinson Cancer Research Center Immunotherapy targeting kras or her2 antigens
EP3841123A2 (en) 2018-08-23 2021-06-30 Seagen Inc. Anti-tigit antibodies
CN110511912B (zh) * 2018-08-30 2024-03-22 浙江煦顼技术有限公司 免疫细胞的功能调节
WO2020068702A1 (en) 2018-09-24 2020-04-02 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
JP7558935B2 (ja) 2018-11-09 2024-10-01 フレッド ハッチンソン キャンサー センター メソテリンを標的とする免疫療法
SI3898668T1 (sl) 2018-12-19 2024-02-29 Humabs Biomed Sa Protitelesa, ki nevtralizirajo virus hepatitisa B in njihove uporabe
EP3908372A1 (en) * 2019-01-13 2021-11-17 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Antibodies specific to human nectin-2
GB2613715B (en) 2019-02-20 2023-12-06 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
BR112021017703A8 (pt) 2019-03-11 2023-04-18 Hutchinson Fred Cancer Res Receptores de células t wt1 de alta avidez e usos dos mesmos
US12559559B2 (en) 2019-07-11 2026-02-24 Dana-Farber Cancer Institute, Inc. Targeting Galectin-9 as a therapeutic strategy for T-cell exhaustion in T-cell acute lymphoblastic leukemia
KR20220050176A (ko) 2019-08-20 2022-04-22 프레드 헛친슨 켄서 리서치 센터 Wt-1에 특이적인 t-세포 면역요법
US20220380441A1 (en) 2019-08-29 2022-12-01 Vir Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
EP3789485A1 (en) * 2019-09-06 2021-03-10 ONK Therapeutics Limited Cellular therapies for cancer
KR20220082007A (ko) 2019-10-08 2022-06-16 넥틴 테라퓨틱스 리미티드 폴리오바이러스 수용체(pvr)에 대한 항체 및 이의 용도
WO2021113831A1 (en) 2019-12-05 2021-06-10 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
WO2021257124A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
BR112022026316A2 (pt) 2020-06-24 2023-03-07 Vir Biotechnology Inc Anticorpos neutralizantes do vírus da hepatite b engenheirados e usos dos mesmos
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
CN114163532A (zh) * 2020-09-10 2022-03-11 南京北恒生物科技有限公司 包含新型共刺激结构域的嵌合抗原受体及其用途
IL299766A (en) * 2020-09-14 2023-03-01 Amgen Inc Method of making lyophilized protein formulations
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
EP4217387A2 (en) 2020-09-24 2023-08-02 Fred Hutchinson Cancer Center Immunotherapy targeting sox2 antigens
WO2022076353A1 (en) 2020-10-06 2022-04-14 Fred Hutchinson Cancer Research Center Compositions and methods for treating mage-a1-expressing disease
US20250032540A1 (en) 2020-12-14 2025-01-30 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2022145879A1 (ko) * 2020-12-28 2022-07-07 연세대학교 산학협력단 면역 관문 저해제의 스크리닝 방법
JP2024504167A (ja) 2021-01-26 2024-01-30 ヴィア・バイオテクノロジー・インコーポレイテッド Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法
CN117377692A (zh) 2021-04-23 2024-01-09 苏州逻晟生物医药有限公司 Tim-3-靶向抗体及其用途
CA3217279A1 (en) 2021-05-04 2022-11-10 Olga Ignatovich Anti-tigit antibodies and methods of use thereof
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
TW202317602A (zh) 2021-07-15 2023-05-01 福瑞德哈金森腫瘤中心 嵌合多肽
CN118871463A (zh) 2021-07-28 2024-10-29 基因泰克公司 用于治疗癌症的方法和组合物
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
CA3243763A1 (en) 2022-02-28 2023-08-31 Nectin Therapeutics Ltd. Humanized antibodies directed against nectin-2 and their drug conjugates
CA3259975A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2023230439A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof
JP2025523387A (ja) 2022-06-07 2025-07-23 ジェネンテック， インコーポレイテッド 抗ｐｄ－ｌ１アンタゴニストおよび抗ｔｉｇｉｔアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025081123A1 (en) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Methods and compositions for improving t cell immunotherapy
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
AU2025227506A1 (en) * 2024-03-01 2026-08-13 Amgen Research (Munich) Gmbh Cd19-selective t cell engaging molecule for treating autoimmune diseases/ autoimmune conditions
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074324A2 (en) * 2003-02-24 2004-09-02 Xerion Pharmaceuticals Ag Modulation of the poliovirus receptor function
EP2067791A1 (en) * 2006-10-06 2009-06-10 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for cancer
WO2009097394A2 (en) * 2008-01-29 2009-08-06 The Brigham And Women's Hospital, Inc. Methods for modulating a population of myeloid-derived suppressor cells and uses thereof
WO2011159877A2 (en) * 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
WO2012177788A1 (en) * 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
WO2015009856A2 (en) * 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
WO2015048312A1 (en) * 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015117002A1 (en) * 2014-01-31 2015-08-06 Novartis Ag Antibody molecules to tim-3 and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
ES2207278T3 (es) 1998-07-28 2004-05-16 Micromet Ag Heterominicuerpos.
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
WO2005107799A1 (ja) * 2004-05-06 2005-11-17 Eisai R & D Management Co., Ltd. 抗Necl-5抗体を有効成分として含む癌治療剤
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
WO2009126688A2 (en) 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
WO2014089169A2 (en) * 2012-12-04 2014-06-12 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
WO2014151910A1 (en) 2013-03-15 2014-09-25 Amgen Inc. Heterodimeric bispecific antibodies
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
WO2015048272A1 (en) 2013-09-25 2015-04-02 Amgen Inc. V-c-fc-v-c antibody
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074324A2 (en) * 2003-02-24 2004-09-02 Xerion Pharmaceuticals Ag Modulation of the poliovirus receptor function
EP2067791A1 (en) * 2006-10-06 2009-06-10 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for cancer
WO2009097394A2 (en) * 2008-01-29 2009-08-06 The Brigham And Women's Hospital, Inc. Methods for modulating a population of myeloid-derived suppressor cells and uses thereof
WO2011159877A2 (en) * 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
WO2012177788A1 (en) * 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
WO2015009856A2 (en) * 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
WO2015048312A1 (en) * 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015117002A1 (en) * 2014-01-31 2015-08-06 Novartis Ag Antibody molecules to tim-3 and uses thereof

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BREANNE LANDRY, JULIANA VALENCIA-SERNA, HILAL GUL-ULUDAG, XIAOYAN JIANG, ANNA JANOWSKA-WIECZOREK, JOSEPH BRANDWEIN AND HASAN ULUDA: "Progress in RNAi-mediated Molecular Therapy of Acute and Chronic Myeloid Leukemia.", MOLECULAR THERAPY-NUCLEIC ACIDS, CELL PRESS, US, vol. 4, 12 May 2015 (2015-05-12), US , pages 1 - 23, XP002763684, ISSN: 2162-2531, DOI: 10.1038/mtna.2015.13 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1 December 2014 (2014-12-01), VARGHESE BINDU ET AL: "A Novel CD20xCD3 Bispecific Fully Human Antibody Induces Potent Anti-Tumor Effects Against B Cell Lymphoma in Mice", XP002765634 *
HOU SHENGKE ET AL: "Recombinant soluble CD226 protein directly inhibits cancer cell proliferation in vitro.", EFFECT OF THE LIPOPOLYSACCHARIDE ANTAGONIST PLANKTOTHRIX SP. FP1 CYANOBACTERIAL EXTRACT ON HUMAN POLYMORPHONUCLEAR LEUKOCYTES., vol. 19, no. 1, 1 March 2014 (2014-03-01), pages 119 - 126, XP002763680, ISSN: 1878-1705 *
JOHN LIZA B ET AL: "Blockade of PD-1 immunosuppression boosts CAR T-cell therapy", ONCOIMMUNOLOGY, vol. 2, no. 10, 1 October 2013 (2013-10-01), XP002765631, DOI: 10.4161/onci.26286 *
KONG YAXIAN ET AL: "T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients.", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 22, no. 12, 15 June 2016 (2016-06-15), US, pages 3057 - 3066, XP002763681, ISSN: 1078-0432 *
KRUPKA C ET AL: "Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.", LEUKEMIA, SPRINGER NATURE PUBLISHING AG, GB, vol. 30, no. 2, 4 August 2015 (2015-08-04), GB, pages 484 - 491, XP002763683, ISSN: 1476-5551 *
KURODA JUNYA ET AL: "Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia.", MOLECULAR CANCER RESEARCH : MCR DEC 2011, vol. 8, no. 7, 1 July 2010 (2010-07-01), pages 994 - 1001, XP002765632, ISSN: 1557-3125, DOI: 10.1158/1541-7786.MCR-10-0040 *
Magee: "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991216/pdf/2051-1426-1-S1-P22.pdf", https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991216/pdf/2051-1426-1-S1-P22.pdf, 7 November 2013 (2013-11-07), XP002763686, Retrieved from the Internet: URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991216/pdf/2051-1426-1-S1-P22.pdf[retrieved on 2016-11-01]the whole document *
PENDE DANIELA ET AL: "PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis.", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 42, no. 4, 1 February 2005 (2005-02-01), GB , pages 463 - 469, XP002763679, ISSN: 0161-5890 *
Q. ZHOU, M. E. MUNGER, R. G. VEENSTRA, B. J. WEIGEL, M. HIRASHIMA, D. H. MUNN, W. J. MURPHY, M. AZUMA, A. C. ANDERSON, V. K. KUCHR: "Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia", BLOOD, vol. 117, no. 17, 28 April 2011 (2011-04-28), pages 4501 - 4510, XP055147794, ISSN: 00064971, DOI: 10.1182/blood-2010-10-310425 *
SANCHEZ-CORREA B, CAMPOS C, PERA A, BERGUA J M, ARCOS M J, BAñAS H, CASADO J G, MORGADO S, DURAN E, SOLANA R, TARAZONA R: "Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 65, no. 4, 1 April 2016 (2016-04-01), Berlin, DE , pages 453 - 463, XP002763685, ISSN: 1432-0851, DOI: 10.1007/s00262-015-1720-6 *
STAMM HAUKE ET AL: "Expression of Novel Immune Checkpoint Molecules PVR and PVRL2 Confers a Negative Prognosis to Patients with Acute Myeloid Leukemia and Their Blockade Augments T-Cell Mediated Lysis of AML Cells Alone or in Combination with the BiTE Antibody Construct AMG 330", BLOOD, & 57TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ORLANDO, FL, USA; DECEMBER 05 -08, 2015, vol. 126, no. 23, 1 December 2015 (2015-12-01), & 57TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ORLANDO, FL, USA; DECEMBER 05 -08, 2015 , XP002763682 *
WO 2004/074324 A2 *
YOSHIKANE KIKUSHIGE, KOICHI AKASHI: "TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES., vol. 1266, no. 1, 17 August 2012 (2012-08-17), pages 118 - 123, XP055087894, ISSN: 00778923, DOI: 10.1111/j.1749-6632.2012.06550.x *
ZHU YUWEN ET AL: "Identification of CD112R as a novel checkpoint for human T cells.", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIV. PRESS, NEW YORK, NY, USA, vol. 213, no. 2, 8 February 2016 (2016-02-08), New York, NY, USA , pages 167 - 176, XP002763687, ISSN: 1540-9538 *

Also Published As

Publication number Publication date
MX2018001351A (es) 2018-05-22
IL256874B (en) 2022-05-01
US20190077869A1 (en) 2019-03-14
WO2017021526A1 (en) 2017-02-09
CA2996015A1 (en) 2017-02-09
NZ738492A (en) 2025-05-30
HUE053763T2 (hu) 2021-12-28
JP7170532B2 (ja) 2022-11-14
US20170037133A1 (en) 2017-02-09
CN108473572A (zh) 2018-08-31
LT3331915T (lt) 2021-06-10
ZA201708598B (en) 2021-04-28
PH12018500120A1 (en) 2018-07-23
AU2016301961B2 (en) 2021-10-07
ES2861436T3 (es) 2021-10-06
EP3331915A1 (en) 2018-06-13
AU2016301961A1 (en) 2018-01-18
JP2018531215A (ja) 2018-10-25
JO3620B1 (ar) 2020-08-27
SG10202000914VA (en) 2020-03-30
TW201718002A (zh) 2017-06-01
MX389204B (es) 2025-03-20
HK1249524A1 (en) 2018-11-02
DK3331915T3 (da) 2021-05-03
UA125375C2 (uk) 2022-03-02
IL256874A (en) 2018-03-29
EP3331915B1 (en) 2021-02-17
SI3331915T1 (sl) 2021-08-31
MY186582A (en) 2021-07-28
TWI719041B (zh) 2021-02-21
EA201890428A1 (ru) 2018-07-31
CN108473572B (zh) 2021-10-15

Similar Documents

Publication Publication Date Title
EP3331915B1 (en) Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers
JP2018531215A6 (ja) 血液由来のがんの治療における使用を目的とする免疫チェックポイント阻害物質
EP3043794B1 (en) Combination of epigenetic factors and bispecific compounds targeting cd33 and cd3 in the treatment of myeloid leukemia
EP3423495B1 (en) Antibodies specific to human poliovirus receptor (pvr)
CA3139025A1 (en) Tigit and pd-1/tigit-binding molecules
CN111201038A (zh) Psgl-1拮抗剂及其用途
US20240199756A1 (en) Bispecific antibodies targeting nkp46 and cd38 and methods of use thereof
JP7840569B2 (ja) ヒト４－１ｂｂアゴニスト抗体およびその使用方法
CA2996015C (en) Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers
HK1249524B (en) Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers
KR20240019073A (ko) Nkp46 및 gpc3를 표적으로 하는 이중 특이적 항체 및 이의 사용 방법
HK1225975B (en) Combination of epigenetic factors and bispecific compounds targeting cd33 and cd3 in the treatment of myeloid leukemia